Stock ATRX ADHERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 11:58:11 2024-05-14 am EDT 		5-day change 1st Jan Change
0.0081 USD +55.77% Intraday chart for Adhera Therapeutics, Inc. +55.77% -73.00%
Jan. 18 Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement CI
Jan. 16 Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 17.36 3.013 0.6304 0.4612 1.17 2.592
Enterprise Value (EV) 1 19.16 -0.905 5.91 6.778 7.757 11.14
P/E ratio -2.61 x -0.17 x -0.05 x -0.09 x -0.11 x -0.69 x
Yield - - - - - -
Capitalization / Revenue - 39,551,492 x 2,501,714 x - - -
EV / Revenue - -11,879,085 x 23,454,095 x - - -
EV / EBITDA -3.55 x 0.09 x -0.58 x -3.47 x - -
EV / FCF -528 x 0.13 x -2.43 x 2.93 x 0.85 x -1.84 x
FCF Yield -0.19% 797% -41.1% 34.1% 118% -54.4%
Price to Book 38.7 x 1.03 x -0.06 x -0.03 x -0.05 x -0.12 x
Nbr of stocks (in thousands) 526 538 543 556 790 3,161
Reference price 2 33.00 5.600 1.160 0.8300 1.480 0.8200
Announcement Date 4/17/18 4/16/19 4/14/20 4/7/21 4/15/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - 0.0762 0.252 - - -
EBITDA 1 -5.39 -10.29 -10.12 -1.955 - -
EBIT 1 -5.841 -10.62 -10.2 -2.037 -0.674 -1.618
Operating Margin - -13,938.42% -4,047.62% - - -
Earnings before Tax (EBT) 1 -6.219 -16.75 -11.98 -3.766 -6.351 -2.114
Net income 1 -6.219 -16.75 -11.98 -3.766 -6.351 -2.114
Net margin - -21,992.17% -4,753.17% - - -
EPS 2 -12.65 -32.88 -24.87 -9.757 -12.93 -1.185
Free Cash Flow 1 -0.0363 -7.214 -2.43 2.314 9.144 -6.059
FCF margin - -9,469.3% -964.19% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/17/18 4/16/19 4/14/20 4/7/21 4/15/22 3/31/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 1.8 - 5.28 6.32 6.59 8.55
Net Cash position 1 - 3.92 - - - -
Leverage (Debt/EBITDA) -0.3339 x - -0.5218 x -3.231 x - -
Free Cash Flow 1 -0.04 -7.21 -2.43 2.31 9.14 -6.06
ROE (net income / shareholders' equity) -339% -993% 344% 30.5% 31.9% 8.94%
ROA (Net income/ Total Assets) -59% -117% -229% -605% -428% -735%
Assets 1 10.54 14.29 5.224 0.6227 1.485 0.2874
Book Value Per Share 2 0.8500 5.440 -18.20 -26.60 -29.50 -7.020
Cash Flow per Share 2 0.2000 7.280 0.0900 0 0.0900 0.0100
Capex - 0.07 - - - -
Capex / Sales - 97.61% - - - -
Announcement Date 4/17/18 4/16/19 4/14/20 4/7/21 4/15/22 3/31/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADHERA THERAPEUTICS, INC. Stock Adhera Therapeutics, Inc.
-73.00% 94.18K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.29% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 104B
ARGENX SE Stock argenx SE
+0.79% 22.28B
BIONTECH SE Stock BioNTech SE
-11.90% 22.41B
GENMAB A/S Stock Genmab A/S
-5.29% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.36% 18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-5.17% 17.89B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.70% 14.28B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.65% 12.55B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATRX Stock
  4. Financials Adhera Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW